AXSOME THERAPEUTICS INC

NASDAQ: AXSM (Axsome Therapeutics, Inc.)

Kemas kini terakhir: 08 May, 6:09AM

112.16

-4.33 (-3.72%)

  • 1H -3.72%
  • 5H 1.82%
  • 1B 2.04%
  • 6B 14.19%
  • Tahun Ke Tarikh 28.45%
  • 1T 49.13%
  • 5T 45.70%
Penutupan Terdahulu 116.49
Buka 115.76
Jumlah Dagangan 701,239
Purata Dagangan (3B) 867,245
Modal Pasaran 5,680,679,936
Harga / Jualan (P/S) 13.20
Harga / Buku (P/B) 90.89
Julat 52 Minggu
64.11 (-42%) — 139.13 (24%)
Tarikh Pendapatan 4 Aug 2025 - 8 Aug 2025
Margin Keuntungan -74.47%
Margin Operasi (TTM) -51.89%
EPS Cair (TTM) -5.99
Pertumbuhan Hasil Suku Tahunan (YOY) 66.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 338.43%
Nisbah Semasa (MRQ) 2.11
Aliran Tunai Operasi (OCF TTM) -128.41 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -28.71 M
Pulangan Atas Aset (ROA TTM) -27.28%
Pulangan Atas Ekuiti (ROE TTM) -231.63%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Menurun Menurun
Biotechnology (Global) Menurun Menurun
Stok Axsome Therapeutics, Inc. Menaik Menaik

AISkor Stockmoo

1.0
Konsensus Penganalisis 5.0
Aktiviti Orang Dalam NA
Volatiliti Harga -0.5
Purata Bergerak Teknikal -2.5
Osilator Teknikal 2.0
Purata 1.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
AXSM 6 B - - 90.89
EXEL 12 B - 19.32 4.73
CORT 8 B - 67.52 12.21
MDGL 6 B - - 9.36
ADMA 5 B - 23.45 15.26
SLNO 4 B - - 14.92

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 16.59%
% Dimiliki oleh Institusi 79.23%

Pemilikan

Nama Tarikh Syer Dipegang
Alethea Capital Management, Llc 30 Sep 2024 738,503
184.10184.10149.30149.30114.50114.5079.7079.7044.9044.90Harga Sasaran MedianQ3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
64.11 (-42%) — 139.13 (24%)
Julat Harga Sasaran
153.00 (36%) — 216.00 (92%)
Tinggi 216.00 (Mizuho, 92.58%) Beli
Median 180.00 (60.49%)
Rendah 153.00 (Needham, 36.41%) Beli
Purata 181.29 (61.64%)
Jumlah 7 Beli
Harga Purata @ Panggilan 110.64
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 22 May 2025 180.00 (60.49%) Beli 108.30
07 May 2025 180.00 (60.49%) Beli 110.86
Baird 06 May 2025 162.00 (44.44%) Beli 112.16
03 Mar 2025 160.00 (42.65%) Beli 127.15
Wells Fargo 06 May 2025 165.00 (47.11%) Beli 112.16
RBC Capital 29 Apr 2025 193.00 (72.08%) Beli 109.92
Jefferies 07 Apr 2025 200.00 (78.32%) Beli 98.50
Needham 01 Apr 2025 153.00 (36.41%) Beli 111.67
03 Mar 2025 153.00 (36.41%) Beli 127.15
Mizuho 27 Mar 2025 216.00 (92.58%) Beli 121.77

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
29 May 2025 Pengumuman Axsome Therapeutics to Participate in Upcoming Investor Conferences
28 May 2025 Pengumuman Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
13 May 2025 Pengumuman Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
05 May 2025 Pengumuman Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
01 May 2025 Pengumuman Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
22 Apr 2025 Pengumuman Axsome Therapeutics to Participate in Upcoming Investor Conferences
08 Apr 2025 Pengumuman Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
04 Apr 2025 Pengumuman Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
01 Apr 2025 Pengumuman Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
25 Mar 2025 Pengumuman Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
03 Mar 2025 Pengumuman Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Papar semua
113.17113.17109.48109.48105.79105.79102.10102.1098.4198.41May 8May 8May 9May 9May 12May 12May 13May 13May 14May 14May 15May 15May 16May 16May 19May 19

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.0000.000-0.500-0.500-1.000-1.000-1.500-1.500-2.000-2.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda